2015
DOI: 10.1016/j.addr.2015.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Vaginal gene therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 32 publications
(14 citation statements)
references
References 115 publications
(133 reference statements)
0
14
0
Order By: Relevance
“…Advantages over other routes of drug administration include low drug doses, reduced risk of systemic immune activation, site-specific delivery, and most importantly, circumvention of first-pass hepatic clearance [4]. The ease of administration and low toxicity profile make the vaginal route an excellent site for the delivery of many drugs and particularly for siRNA delivery for the treatment and prevention of vaginal and/or cervical diseases [5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Advantages over other routes of drug administration include low drug doses, reduced risk of systemic immune activation, site-specific delivery, and most importantly, circumvention of first-pass hepatic clearance [4]. The ease of administration and low toxicity profile make the vaginal route an excellent site for the delivery of many drugs and particularly for siRNA delivery for the treatment and prevention of vaginal and/or cervical diseases [5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Control and measurement of the siRNA complexation efficiency with liposomes are crucial steps in formulation development. A high loading efficiency is generally seeked . Indeed, the loading efficiency of siRNA into the carrier system plays a critical role in determining silencing efficiencies.…”
Section: Resultsmentioning
confidence: 99%
“…The use of small interfering RNA (siRNA) is a promising approach to treat human diseases, including inflammatory disorders, viral infections and cancers . siRNA are short double‐stranded RNA molecules (21–23 oligonucleotides base pairs) able to specifically recognize a complementary mRNA, to degrade it and consequently to reduce its translation into proteins .…”
Section: Introductionmentioning
confidence: 99%
“…However, the induction of the immune response and inflammation limits the application of viral vectors to inflammatory diseases, including cornea inflammation, even considering its relative immune privilege [ 1 ]. Moreover, they have been frequently administered by invasive methods such as intrastromal, intralimbal, intracameral, or after removing the corneal epithelium [ 30 , 31 , 32 ]. Non-viral gene therapy has proven to be a feasible alternative for corneal gene therapy even after topical administration [ 33 , 34 , 35 , 36 ].…”
Section: Discussionmentioning
confidence: 99%